Antibody-Drug Conjugates (ADCs) now represent roughly 20% of the antibody-based cancer therapies in development, combining three essential elements: a monoclonal antibody to target specific cancer receptors, a highly potent cytotoxic payload, and a specialized linker that connects the two.

On the efficacy front, there's remarkable variation among ADCs in payload types, linker chemistries, and drug to antibody ratios—all crucial levers that influence therapeutic effect. From a safety standpoint, unintended toxicities can emerge from any of the three components, underscoring the complexity inherent in balancing design, manufacturing, and clinical performance.

This multi dimensional challenge makes the path to approval especially demanding—requiring seamless integration of design precision, rigorous testing, and regulatory acumen.

This white paper charts the remarkable journey of Antibody-Drug Conjugates (ADCs)—a breakthrough modality in oncology that realizes Paul Ehrlich’s century-old "magic bullet" vision through modern innovation.